vol 21, no. 4, 1995 clozapine: efficacy and safety · tabl e 1. efficac y o f clozapin e fo r acut...
Post on 28-Jan-2020
1 Views
Preview:
TRANSCRIPT
VOL 21, NO. 4, 1995 Clozapine: Efficacyand Safety
579
by Robert W. Buchanan Abstract
Clozapine (Clozaril) representsthe first major advance in thepharmacological treatment ofschizophrenia since the introduc-tion of antipsychotics into clini-cal practice in the 1950s. Studiesconsistently support its efficacyfor reducing positive symptomsin acutely psychotic patients andin treatment-resistant patients,for preventing positive symptomexacerbations as a maintenancetreatment, and for reducingsymptoms of hostility and vio-lence. There is evidence to sug-gest that clozapine may improvesocial and occupational function-ing and quality of life and mayreduce affective symptoms, hos-pitalizations, secondary negativesymptoms, and tardive dys-kinesia. Its most significant sideeffects include agranulocytosis,seizures, weight gain, hypoten-sion and tachycardia, sedation,and perhaps rebound psychosis(with abrupt discontinuation ofmedication).
Schizophrenia Bulletin, 21(4):579-591, 1995.
Clozapine (Clozaril) represents thefirst major advance in the pharma-cological treatment of schizophre-nia since the introduction of anti-psychotics into clinical practice inthe 1950s. The introduction ofclozapine and further research re-garding its novel clinical effectshave stimulated renewed interestin drug development and fosteredseveral hypotheses regarding waysin which the efficacy or adverseeffects profile of antipsychoticdrugs might be improved.
First manufactured in 1959,clozapine is a dibenzodiazepine
derivative with unique preclinicaland clinical characteristics. In pre-clinical studies, clozapine, likeother antipsychotic drugs, blocksconditioned avoidance behaviors, ameasure that is considered predic-tive of antipsychotic activity (Fittonand Heel 1990). However, unlikeother antipsychotic drugs, cloza-pine does not cause catalepsy,block apomorphine- or ampheta-mine-induced stereotyped be-haviors, elevate serum prolactin, orcause dopamine receptor hypersen-sitivity in laboratory animals (Fit-ton and Heel 1990). Clozapine isfurther distinguished from otherantipsychotic drugs by its rela-tively higher affinity for D, thanfor D2 dopaminergic receptors, itshigher affinity for 5-HT2a seroto-nergic than'for D2 dopaminergicreceptors, and its strong affinityfor the D4 dopaminergic receptor(Baldessarini and Frankenburg1991; Jann 1991; Meltzer 1993).Clozapine is also highly anti-cholinergic and has significant al-phaj and alpha2 antiadrenergicproperties (Baldessarini and Fran-kenburg 1991; Jann 1991). In clini-cal studies, clozapine has beenshown to have differential clinicalefficacy for treatment-resistantschizophrenia patients and to beassociated with a low incidence ofextrapyramidal side effects (EPS)(Kane et al. 1988). The combina-tion of these preclinical and clini-cal characteristics has led clozapineto be termed an "atypical antipsy-chotic" (Kane et al. 1988).
This review addresses the fol-lowing questions:
Reprint requests should be sent toDr. R.W. Buchanan, Maryland Psychi-atric Research Center, P.O. Box 21247,Baltimore, MD 21228
580 SCHIZOPHRENIA BULLETIN
1. What is the efficacy (vs.placebo and/or conventional anti-psychotics) of clozapine duringacute symptom episodes for reduc-tion of positive symptoms,negative/deficit symptoms (i.e.,primary, enduring negative symp-toms), and other outcomes?
2. What is the efficacy (vs.placebo and/or conventional anti-psychotics) of clozapine duringmaintenance treatment for reductionof positive symptoms, negative/deficit symptoms, and otheroutcomes?
3. Is clozapine efficacious forschizophrenia patients who fail torespond to conventional anti-psychotics?
4. What are the side effects andrisks associated with clozapine?
Methods
Computerized searches of MED-LINE, MEDLARS, and PSYCLITdata bases were conducted back to1966. In addition, the references inarticles obtained from the comput-erized searches were checked toensure that relevant articles nototherwise identified were included.Conference abstracts, book chap-ters, and unpublished data are notincluded in this review.
The inclusion and exclusion cri-teria used to select studies varyfor the different review questions,reflecting the different levels ofprogress in the investigation ofdifferent outcome measures, andthe different levels of feasibility inthe conduct of methodologicallyrigorous studies for each outcome.The clinical efficacy of clozapinefor two outcomes, positive andnegative symptoms, in acutely psy-chotic patients and in treatment-resistant schizophrenia patients hasbeen most extensively studied.
Therefore, the selection criteria forprimary articles addressing thesetwo outcomes in these two popu-lations are the most rigorous: (1)the study must have been a ran-domized, double-blind trial; (2) thestudy must have used standard-ized, structured rating instrumentsto measure positive and negativesymptoms; and (3) the article mustbe in English.
The studies examining the useof clozapine as a maintenancetreatment are not as methodologi-cally rigorous as those examiningthe drug's clinical efficacy inacutely psychotic or treatment-resistant patients. This is largelyowing to the difficulty in conduct-ing long-term prospective double-blind trials of maintenance treat-ment. Therefore, the selection crite-ria studies addressing this issuewere expanded to include open-labeled, retrospective, and prospec-tive followup studies that ex-amined clozapine's efficacy as amaintenance treatment. And be-cause the literature evaluatingclozapine's efficacy for other out-come measures (i.e., violent be-havior and affective symptoms) isnot as extensive as that in otherareas, the selection criteria forthose studies were expanded to in-clude open-labeled studies andcase reports that use standardized,structured rating instruments (ifapplicable), in addition to double-blind studies. All articles and let-ters that provide primary informa-tion on clozapine's side effects andare written in English were in-cluded. The rationale for usingsuch broad criteria is the inherentnature of side effects (i.e., theymay be rare in occurrence), whichmeans that management strategiesfor treating serious or life-threatening side effects often can-
not be evaluated in a method-ologically rigorous manner.
Findings
What Is the Efficacy (vs. Placeboand/or Conventional Antipsy-chotics) of Clozapine DuringAcute Symptom Episodes for Re-duction of Positive Symptoms,Negative/Deficit Symptoms, andOther Outcomes? Nine studies ofthe efficacy of clozapine foracutely psychotic patients met thereview criteria and are sum-marized in table 1. Most of thesestudies found clozapine to beequally or more effective than tra-ditional neuroleptics (Ekblom andHaggstrom 1974; Gerlach et al.1974; Singer and Law 1974; Chiuet al. 1976; Guirguis et al. 1977;Gelenberg and Doller 1979; Shop-sin et al. 1979; Claghom et al.1987). Only the study by Fischer-Cornelssen and Ferner (1976) failedto find clozapine to be at least aseffective as traditional neuroleptics.Specifically, these authors reporttrifluoperazine to be more effectivethan clozapine but note that thismay have been related to meth-odological problems surroundingthe dosage schedule for clozapine.The uniformity of these findingssuggests that clozapine is at leastas effective as traditional neurolep-tics for the treatment of acutely illschizophrenia patients. However,these studies are characterized bysmall sample sizes or by the useof low dosages of either clozapineor chlorpromazine. These meth-odological limitations preclude adefinitive conclusion that clozapineis more effective than traditionalneuroleptics for acutely ill schizo-phrenia patients, and leave openthe highly unlikely possibility thatclozapine is less effective.
Tab
le
1.
Eff
icac
y of
clo
zap
ine
for
acu
te
psy
cho
sis
o
Stu
dy
Ch
arac
teri
stic
s:d
esig
n,
loca
tio
n,
du
rati
on
,sa
mp
le
size
Ou
tco
mes
re
sult
s
Co
mp
aris
on
trea
tmen
tsP
osi
tive
sym
pto
ms
Neg
ativ
esy
mp
tom
sS
ide
effe
cts
Oth
er
Ekb
lom
an
d D
oubl
e-bl
ind,
par
alle
l C
hlor
prom
azin
e N
ot
sign
ifica
ntH
aggs
trom
gr
oups
; in
patie
nt;
40
(CP
Z)
(NS
)(1
974)
da
ys;
n =
41
Ger
lach
et
al.
(197
4)D
oubl
e-bl
ind,
cro
ss-
ove
r; i
npat
ient
; 8
wee
ks;
n =
20
Hal
oper
idol
(HD
L)C
LZ =
HD
L fo
rB
PR
S
psyc
hotic
sym
ptom
s;
CLZ
>
HD
L fo
rB
PR
S
conc
ep-
tual
dis
orga
niza
-tio
n
Clo
zapi
ne
(CLZ
)>
C
PZ
on
BP
RS
em
otio
nal
with
draw
al
CLZ
= H
DL
for
BP
RS
an
ergi
a
No
extr
apyr
ami-
dal
side
ef
fect
s(E
PS
) in
eith
ergr
oup
CLZ
<
H
DL
for
EP
S
Not
as
sess
ed(N
A)
CLZ
>
H
DL
for
BP
RS
an
xiet
y
CO
CO
O1
Sin
ger
and
Law
(1
974)
Chi
u et
al.
(197
6)
Fis
cher
-C
omel
ssen
an
d F
erne
r(1
976)
Gui
rgui
s et
al.
(197
7)
Gel
enbe
rgan
d D
olle
r(1
979)
Sho
psin
et
al.
(197
9)
Cla
ghor
n et
al.
(198
7)
Dou
ble-
blin
d, p
aral
lel
grou
ps;
inpa
tient
; 40
days
; n
= 3
8D
oubl
e-bl
ind,
pa
ralle
lgr
oups
; in
patie
nt;
6w
eeks
; n
= 6
4D
oubl
e-bl
ind,
pa
ralle
lgr
oups
; in
patie
nt(m
ultic
ente
r);
7w
eeks
; n
= 7
23D
oubl
e-bl
ind,
pa
ralle
lgr
oups
; in
patie
nt;
7w
eeks
; n
= 5
0D
oubl
e-bl
ind,
pa
ralle
lgr
oups
; in
patie
nt;
4-8
w
eeks
; n
= 1
5D
oubl
e-bl
ind,
pa
ralle
lgr
oups
; in
patie
nt;
5w
eeks
; n
= 3
1D
oubl
e-bl
ind,
pa
ralle
lgr
oups
; in
patie
nt;
in-
patie
nt
(mul
ticen
ter)
;2
8-5
6 da
ys;
n =
151
CP
Z
CP
Z
CP
Z,
HD
L, t
ri-
fluop
eraz
ine,
clop
enth
ixol
CP
Z
CP
Z
CP
Z,
plac
ebo
CP
Z
NS
NS
CLZ
>
H
DL
NS
CLZ
>
C
PZ
on
BP
RS
th
ough
tdi
sord
erN
S
CLZ
>
C
PZ
on
BP
RS
th
ough
tdi
sord
er
NS
NS
CLZ
>
CLZ
>
BP
RS
CLZ
>
BP
RS
NS
CLZ
>
BP
RS
HD
L
CP
Z o
nan
ergi
a
CP
Z o
nan
ergi
a
CP
Z o
nan
ergi
a
NA
NA
NS
NA
NA
NA
CLZ
<
C
PZ
for
EP
S
NA
NA
NA
NA
NA
CLZ
>
C
PZ
on
BP
RS
de
pres
sion
CLZ
>
C
PZ
on
BP
RS
ho
stili
ty/
susp
icio
usne
ss
Not
e.—
BP
RS
=
B
rief
Psy
chia
tric
R
atin
g S
cale
(O
vera
ll an
d G
orha
m
1962
).
oo
582 SCHIZOPHRENIA BULLETIN
None of the studies used spe-cific assessments of negative symp-toms, and there was no attempt todifferentiate the effect of clozapineon deficit versus secondary nega-tive symptoms. Therefore, defini-tive statements about clozapine'sefficacy for negative symptoms inacutely psychotic patients are notpossible.
Clozapine was observed to beeffective in reducing symptoms ofirritability, hostility, and sus-piciousness (Chiu et al. 1976;Gelenberg and Doller 1979;Claghorn et al. 1987) and of anx-iety and depression (Gerlach et al.1974; Gelenberg and Doller 1979;Shopsin et al. 1979; Claghorn et al.1987). However, none of the stud-ies examined how clozapine's sed-ative actions or its decreased likeli-hood of inducing EPS relate to itstherapeutic effect on these out-comes. Several studies found it tohave a more rapid onset of action,with differences emerging betweenclozapine and the comparison drugby 2 weeks (Ekblom and Hagg-strom 1974; Singer and Law 1974;Claghorn et al. 1987).
What Is the Efficacy (vs. Placeboand/or Conventional Antipsy-chotics) of Clozapine DuringMaintenance Treatment for Re-duction of Positive Symptoms,Negative/Deficit Symptoms, andOther Outcomes? The characteris-tics and findings from the 11 stud-ies that examined clozapine as amaintenance treatment and met re-view criteria are shown in table 2.A number of general limitationsapply to most, if not all, of thesestudies. Specifically, all the retro-spective studies are limited bytheir dependence on medical rec-ords as the major source of infor-mation; their lack of objective
symptom ratings, which precludesthe specific evaluation of positiveand negative symptom response toclozapine treatment; and theirfailure to use objective criteria todefine treatment response. Theprospective studies are charac-terized by small sample sizes andthe lack of nonblind ratings ofoutcome measures. All the retro-spective and prospective studies,except Leon (1979), are limited bythe lack of comparison treatmentgroups, which makes it impossibleto definitively ascribe changes inclinical status to clozapine treat-ment. As a result, definitive con-clusions about the efficacy ofclozapine as a maintenance treat-ment await further study.
The data from these studies thusprovide the following qualifiedconclusions. First, most of the pa-tients included in these studieshad not experienced adequatetreatment responses to traditionalneuroleptics. Therefore, the resultsof these studies provide furthersupport for the proposition thatclozapine has differential efficacyfor schizophrenia patients whodo not respond to traditionalneuroleptics.
Second, the studies provide con-flicting data on the efficacy ofclozapine for negative symptoms.Two studies report a positiveeffect; however, one used a proxymeasure composed of mainly de-pressive symptoms (Meltzer 1992),and the other found negativesymptom change related to changein positive and extrapyramidalsymptoms (Lieberman et al. 1994).The latter finding is similar to ob-servations from uncontrolled short-term treatment studies (Tandon etal. 1993; Miller et al. 1994). Thus,the data suggest that clozapine'seffect on negative symptoms may
be limited. None of the studiesthat examined this effect differenti-ated deficit from secondary nega-tive symptoms.
Third, clozapine treatment ap-pears to be effective in preventingexacerbations of psychotic symp-toms and is associated with de-creased rates of hospitalization(Leon 1979; Meltzer et al. 1990;Breier et al. 1993). However, it isunclear if this advantage exists inpatients who are not treatment re-sistant, nor is it known to whatextent the weekly monitoring re-quired for clozapine treatment maybe related to the decrease in hos-pitalizations that occurs withtreatment.
Fourth, long-term clozapinetreatment is associated with im-proved social and occupationalfunctioning and quality of life.Fifth, clozapine treatment is associ-ated with a significant decrease insuicidal behavior (Meltzer andOkayli 1995). Sixth, the major rea-sons for discontinuing clozapinetreatment are lack of adequatetreatment response, noncompliance,and severe side effects.
Is Clozapine Efficacious forSchizophrenia Patients Who Failto Respond to Conventional An-tipsychotics? Selected characteris-tics and study samples of thethree studies that examined theefficacy of clozapine in treatment-resistant schizophrenia patients andmet review criteria are presentedin table 3. Two studies examinedthe efficacy of clozapine in hospi-talized treatment-resistant patients(Kane et al. 1988; Pickar et al.1992), and one study examined itin treatment-resistant outpatients(Breier et al. 1994). These studies,primarily Kane et al. (1988) andBreier et al. (1994), provide strong
Tab
le 2
. E
ffic
acy
of c
loza
pin
e fo
r m
ain
ten
ance
tr
eatm
ent
Stu
dy
Leon
(197
9)
Juul
-P
ouls
en e
tal
. (1
985)
Kuh
a an
dM
ietti
nen
(198
6)
Lind
stro
m(1
988)
Lepp
ig e
tal
. (1
989)
Mat
tes
(198
9)
Mel
tzer
et
al.
(199
0);
Mel
tzer
(199
2)
Dav
ies
etal
. (1
991)
Ch
arac
teri
stic
s:d
esig
n,
loca
tio
n,
du
rati
on
,sa
mp
le
size
Ret
rosp
ectiv
e ch
art
revi
ew;
loca
tion
not
spec
ified
; 3
-4
year
s;n
=
31
-37
Ret
rosp
ectiv
e ch
art
revi
ew;
inpa
tient
; up
to
12 y
ears
; n
=21
6
Ret
rosp
ectiv
e fo
llow
-up
; in
patie
nt
and
outp
atie
nt;
30
da
ys-
7 ye
ars;
n
= 1
08
Ret
rosp
ectiv
e fo
l-lo
wup
; in
patie
nt
an
dou
tpat
ient
; m
ean
=44
mon
ths;
n =
96
Ret
rosp
ectiv
e ch
art
revi
ew;
outp
atie
nt;
mea
n =
21
mon
ths;
n =
12
1
Cas
e re
port
s, o
pen
tria
l; in
patie
nt
an
dou
tpat
ient
; va
riabl
efo
llow
up;
n =
14
Pro
spec
tive
open
tria
l; in
patie
nt;
6m
onth
s; n
= 3
8
Pro
spec
tive
open
tria
l; in
patie
nt
and
outp
atie
nt;
1 ye
ar;
n =
24
Co
mp
aris
on
trea
tmen
t
Chl
orpr
omaz
ine
(CP
Z)
Prio
r tr
eatm
ent
with
con
ven-
tiona
l an
tipsy
-ch
otic
s
Prio
r tr
eatm
ent
with
con
ven-
tiona
l an
tipsy
-ch
otic
sP
rior
trea
tmen
tw
ith c
on
ven
-tio
nal
antip
sy-
chot
ics
Prio
r tr
eatm
ent
with
con
ven-
tiona
l an
tipsy
-ch
otic
s
Prio
r tr
eatm
ent
with
con
ven-
tiona
l an
tipsy
-ch
otic
s
Prio
r tr
eatm
ent
with
con
ven-
tiona
l an
tipsy
-ch
otic
s
Prio
r tr
eatm
ent
with
con
ven-
tiona
l an
tipsy
-ch
otic
s
Po
siti
vesy
mp
tom
s
Clo
zapi
ne(C
LZ)
>
CP
Z
NA
30%
m
arke
dre
duct
ion;
36
%m
odes
t re
duc-
tion
NA
Dec
reas
ed d
e-lu
sion
s an
d in
-co
here
nce
Dec
reas
edB
PR
S p
sy-
chos
is
Dec
reas
edB
PR
S
psy-
chos
is
NA
Ou
tco
mes
re
sult
s
Neg
ativ
esy
mp
tom
s
Not
as
sess
ed(N
A)
NA
NA
NA
Dec
reas
edan
ergi
a
Dec
reas
edB
PR
S e
mo-
tiona
l w
ith-
draw
al
Dec
reas
edB
PR
S
aner
gia
NA
Glo
bal
NA
Com
pare
d w
ithpr
ior
trea
tmen
ton
co
nven
tiona
lan
tipsy
chot
ics:
51
%
bette
r,47
% u
n-ch
ange
d, 2
%w
orse
NA
43%
glo
bal
im-
prov
emen
t; 3
8%
mod
erat
e im
-pr
ovem
ent
12%
co
mpl
ete
rem
issi
on;
57
%m
arke
dly
im-
prov
ed;
24
%m
ildly
im
prov
edN
A
NA
Ove
rall
sym
p-to
m
redu
ctio
n(t
ype
not
spec
-ifi
ed)
Oth
er
CLZ
>
C
PZ
for
hosp
italiz
atio
nre
duct
ion
NA
NA
Em
ploy
men
t ra
tein
crea
sed
from
3% t
o 3
8%
Dec
reas
ed d
e-pr
essi
on
NA
Impr
oved
qu
ality
of
life;
enh
ance
dem
ploy
men
t; 8
3%
decr
ease
in
hos
pi-
taliz
atio
n
NA
p CO CD 00 CO
584 SCHIZOPHRENIA BULLETIN
tin
ued
oo
trea
tmen
t—
0)ocracSic
mai
for
c
clo
zap
i
o>>on
Eff
icab
le 2
.
CO
resu
l
(00)
Eo
Out
cis
tics
:ca
tio
n.
5 2z .£!
leg
ativ
e
4.
osi
tive
a
co(A
ipar
i;
too
o
23
Oth
erob
al
O
'mp
tom
s
(A
mp
tom
s
(0
c
atm
etr
esi
ze
4)
a.Ea0)
tudy
c/)
spi-
ased
ho
9>
Dec
i
2
sign
ifica
nt
O2
oved
on
£
cCD
E
trea
Prio
rop
en
CD
.5oCDQ .CO
OtX
reie
r et
CO
ion;
im
-
m
taliz
:ov
emen
tim
prza
pine
_gCJ
cCD
conv
with
ent;
1at
i
Q .
O
I. (1
993;
CO
and
d so
cial
CD
prov
i> %COQ .
1 an
titio
na
i nCO
ii
ci_TCOCD
unc-
atio
nal
fO
CC
Itio
n
CO
o
chot
i
2
CD
spon
s
CD
olO
'eas
e in
oCD
Q
ease
in
oCD
a
c:CD
trea
tP
rior
open
CD. ^
OCDQ .CO
Pro
c
eber
ma
i
2
co"
IS a
nerg
i;
nQ.CO
S th
ough
t
rrD.03
CCD
conv
with
nt
and
CD
•J5a.~
tria
l
CO
S
tota
l
2
W
der
oCO
XI
COQ .
1 an
titio
nat
year
;
"?-
:iei
CD
:or
CO
CO
o
chot
i
CO®CL ..
OU
t|99
4)
^ ,
IIc
ased
su
Dec
i
2
<
2
2
cCD
trea
iP
rior
open
CD
.soCDQ .CO
Pro
C
eltz
er a
r>
COCOcu
y,
hope
hci
da
,cCDAU
OO
with
nt
and
CD
toQ .
7.
tria
lan
d-
ness
,coQ.
1 an
titio
na
CD
.9COo _
OU
t|ka
yli
995)
O
ssio
nCDjd
ap
CO
o
chot
iea
rs;
r--CO CN
c .o »E c
en
1984
).
cflCD
" DC
oS
ympt
egat
ive
z"o
CO
ie
Ass
essm
); S
AN
S
= S
calt
cuo>t~E
oO
cCO
"ra
(Ove
r
CDCO
Rat
ing
Sc
u
iat
a.
Brie
f
n
CO(TQ.CD
support for the proposition thatclozapine exhibits differentialefficacy for treatment-resistantschizophrenia patients, especiallyinpatients. The relatively smallsample in the Breier et al. (1994)study precludes definitive conclu-sions on this score, but the study'sresults, when combined with theresults from the maintenance stud-ies, provide strong presumptiveevidence.
Clozapine was found to beeffective for both positive andnegative symptoms. Its effect onnegative symptoms is restricted tosecondary negative symptoms, andthis effect is related to its en-hanced efficacy for positive symp-toms and the decreased incidenceof EPS. In the only study that ex-amined clozapine's effect on deficitsymptoms, Breier et al. (1994) re-port no effect.
Both Kane et al. (1988) andBreier et al. (1994) found clozapineto be effective for reducing symp-toms of hostility but not ofanxiety/depression. The findings ofclozapine's efficacy for hostilitysymptoms are similar to the find-ings from the studies examiningthe effect of clozapine in acutelypsychotic patients. Kane et al.(1988) note that clozapine exhibitsits differential efficacy by the firstweek of treatment. Breier et al.(1994) do not report any time-of-onset data.
What Are the Side Effects andRisks Associated With Clozapine?Clozapine treatment is associatedwith a broad range of side effects,yet it offers the advantage oflower rates of EPS than those ob-served with conventional anti-psychotics. The most serious ofclozapine's side effects is agranulo-cytosis. Other important side
VOL. 21, NO. 4, 1995 585
nts
Q>
ati
a
tan
t
if)"in£cCD
treal
o»«—0)_c
clo
zap
ouCO
UJ
CO
ab
le
co
(0
£
com
es
3
o
si
o -2 §2-1o£
<u
Neg
ati
V
Pos
c
mp
arii
oo
c
ci>
Oth
(0
EoQ.E
(0EQ
sym
pea
tme
size
CO
tud
y
COt r
CO
o
N_)oCOrxQ_mco
> C
PZ
_iO
A
o
pine
(
re
O
CDCNffl
irpro
mi
Z
1, pa
ral-
1
"5
Dou
l
re
ane
E
•
Q
N
stili
ty
o
re
anei
CODCCO
N
O
CP
i(m
ulti-
c.Sirec
lei;
i19
88)
cgCO
Q.
CODC
COco
«eks
;
CO, _
"if
cent
<iet
y
cre•ocre
0 0
cSIIc
T3CDCOCOCD
CO
re
o
CO
CD
O
> F
LU
O
CODC0_CO
o"̂*
_J_ lLL
AN
1O
CD
c
hena
zir lu
p
"2'—•*?"o
Dou
l
«B
icka
r
a.
LL
II
° COre'Zffco
re o
osis
- Co>,coa.
LL
trol
led,
ipatie
nt
o ~ -
O > CD•g ° 5
•5.0 2
_̂_
15
COrxCLCD
1
I
N_JO
^Occ
> H
DL
O
CO
BP
R
c0
_ iQ
N
O
perid
o
re
"CD
1, pa
rall
c:—
. - ^
•° c\i -S
dura
n =
Dou
l
a3
reie
r
CO
1
QI
N
Minis
0
/AN"10
co"
; pa
tieni
1
osis
CO
a.
xatie
nt;
0
Q .
grou
1. (1
9!
re
c0
CO
CDIS
dxi
ety
« !
c cO CO
m'c
atii
^~
in d
efic
i
i
io^:CD
O
00ex
cIS(/>ct
•o<
toi
aE
:ivo
<a0CDz"5c
0;
Ass
es
CD
e fo
r
CDu
03II
SA
NS
sen
ECO
€0O
rail
and
(Ove
CD
s
Rat
ing S
•gCO
••§>.CO
CL
•cCD
II
<Z>tra.
T•20
effects include orthostatic hypoten-sion and tachycardia, sedation, sei-zures, weight gain, and reboundpsychosis.
Agranulocytosis. Clozapinetreatment is associated with thedevelopment of agranulocytosis(granulocyte count < 500/mm3),neutropenia (granulocyte count <1,500/mm3), and/or leukopenia(white blood cell count [WBC] of< 3,500/mm3) (Safferman et al.1991). The severity of clozapine'seffect on the bone marrow is di-rectly related to how quickly ab-normalities in bone marrow func-tion are detected. Estimates of thecumulative incidence of clozapine-induced agranulocytosis rangefrom 0.05 to 2.0 percent; neu-tropenia is estimated to occur in2.8 percent of patients, and leuko-penia is estimated to occur in atleast 0.3 percent of patients (Fittonand Heel 1990; Stephens 1990; Bal-dessarini and Frankenburg 1991;Safferman et al. 1991; Krupp andBarnes 1992). The range of inci-dence rates for agranulocytosismay be related to differences inpatient characteristics, dosage regi-mens, and treatment duration (Fit-ton and Heel 1990). The risk ofdeveloping agranulocytosis withclozapine treatment is 10 timesgreater than that with traditionalneuroleptics (Fitton and Heel 1990;Meltzer 1993). Clozapine-inducedagranulocytosis is most likely tooccur within the first 6 months oftreatment, with 75 to 80 percent ofall cases occurring within the first4 to 18 weeks (Baldessarini andFrankenburg 1991; Safferman et al.1991; Krupp and Barnes 1992;Meltzer 1993). The peak of newcases occurs at 10 weeks (Kruppand Barnes 1992). The drop inWBC may be precipitous or grad-ual (Meltzer 1993).
586 SCHIZOPHRENIA BULLETIN
Hypotension and tachycardia.Clozapine treatment is commonlyassociated with orthostatic hypo-tension (secondary to clozapine'salpha-adrenergic antagonism; rateof occurrence: 8%-13%) andtachycardia (secondary to cloza-pine's anticholinergic activity; rateof occurrence: 12%-25%) (Borisonand Diamond 1990; Baldessariniand Frankenburg 1991; Saffermanet al. 1991; Meltzer 1993), andboth are dosage dependent. Pa-tients tend to develop tolerance tothese side effects with time (Fittonand Heel 1990; Jann 1991).
Sedation. Sedation, the mostcommon side effect (20%-50%), isprobably related to clozapine'santihistaminergic and anti-alpha]-adrenergic properties (Grohmannet al. 1989; Leppig et al. 1989;Borison and Diamond 1990; Ste-phens 1990; Safferman et al. 1991).Sedation occurs early in treatment,and patients typically become tol-erant to it (Fitton and Heel 1990;Baldessarini and Frankenburg1991).
Seizures. Clozapine treatment,as compared with traditional neu-roleptic treatment, is associatedwith a relatively high risk ofgrand mal seizures (l%-10%) (Fit-ton and Heel 1990; Stephens 1990;Baldessarini and Frankenburg 1991;Devinsky et al. 1991; Liukkonen etal. 1992). There are also reports ofmyoclonic and atonic activity and/or seizures with clozapine treat-ment (Lemus et al. 1989; Chiles etal. 1990; Gouzoulis et al. 1991; Saf-ferman et al. 1991; Berman et al.1992; Szarek and Goethe 1992).The presence of myoclonic jerksmay presage the development offuture grand mal seizures (Bermanet al. 1992). Seizure activity is apotential complication of clozapineoverdoses (Jann 1991); concurrent
neuroleptic treatment may increasethe risk of seizures (Liukkonen etal. 1992).
Electroencephalogram changesand seizures appear to be dosagerelated (Simpson and Cooper 1978;Leppig et al. 1989; Fitton and Heel1990; Haller and Binder 1990; Ste-phens 1990; Baker and Conley1991; Jann 1991; Safferman et al.1991; Meltzer 1993). Devinsky etal. (1991) conducted a retrospectivechart review of 1,418 clozapine-treated patients to examine the re-lationship between clozapine dos-age and seizures. They report thefollowing frequency rates: cloza-pine dosage below 300 mg perday (1%); clozapine dosage below600 mg per day (2.7%); andclozapine dosage above 600 mgper day (4.4%). They also notethat rapid upward titration andthe use of concurrent medicationsthat lower the seizure thresholdwere associated with an increasedlikelihood of developing seizures.
Weight gain. Significant weightgain is commonly observed withclozapine treatment (13%-23%)(Leppig et al. 1989; Carson andForbes 1990; Cohen et al. 1990; Fit-ton and Heel 1990; Leadbetter andVieweg 1990; Baldessarini andFrankenburg 1991; Safferman et al.1991; Lamberti 1992; Leadbetter etal. 1992; Meltzer 1993). The weightgain may be related to clozapine'sserotonergic antagonist actions,since serotonin agonists have beennoted to suppress appetite (Lead-better et al. 1992). Weight gain hasbeen associated with clinical re-sponse; patients who exhibit thegreatest weight gain also exhibitthe best clinical response (Leadbet-ter and Vieweg 1990; Lamberti1992; Leadbetter et al. 1992).
Rebound psychosis. Therehave been reports of rapid deterio-
ration and the onset of new psy-chotic symptoms with abruptclozapine withdrawal (Simpson etal. 1978; Ekblom et al. 1984; Pe-renyi et al. 1985; Eklund 1987;Borison et al. 1988; Stephens 1990;Alphs and Lee 1991; Safferman etal. 1991; Parsa et al. 1993). Thefrequency of this phenomenon isunknown, but patients with higherbaseline symptom levels (Borisonet al. 1988) or longer duration ofclozapine treatment may be morelikely to exhibit the phenomenon.Exacerbations of psychosis follow-ing clozapine withdrawal havebeen shown to be associated withincreased tardive dyskinesia (TD)(Alphs and Lee 1991), suggestingthe possibility that supersensitivityof dopaminergic receptors may un-derlie this phenomenon.
Other side effects. Amongother side effects of clozapine arenausea, vomiting, and constipation(Baldessarini and Frankenburg1991; Safferman et al. 1991); eleva-tion of liver enzymes (up to 10%)(Kirkegaard and Jensen 1979; Ste-phens 1990; Safferman et al. 1991);hypersalivation (12%-40%) (Stephens1990; Baldessarini and Frankenburg1991; Safferman et al. 1991; Meltzer1993); confusion or delirium (3%)(Schuster et al. 1977; Banki andVojnik 1978; Grohmann et al. 1989;Fitton and Heel 1990; Stephens1990; Baldessarini and Frankenburg1991; Safferman et al. 1991); inconti-nence, frequency/urgency, hesi-tancy, urinary retention, or impo-tence (6%) (Safferman et al. 1991;Meltzer 1993); benign hyperthermia(5%-15%) (Fitton and Heel 1990;Stephens 1990; Baldessarini andFrankenburg 1991; Meltzer 1993);and development or exacerbationof obsessive-compulsive symptoms(Baker et al. 1992; Patil 1992;Meltzer 1993). This last phenome-
VOL 21, NO. 4, 1995 587
non may be related to clozapine'santiserotonergic properties (Baker etal. 1992; Patil 1992). There are noknown teratogenic effects of cloza-pine (Meltzer 1993; Waldman andSafferman 1993).
Side effects of other antipsy-chotics less commonly seen withclozapine. Clozapine is associatedwith lower rates of certain sideeffects than are typically observedwith conventional antipsychotics.The incidence of EPS is low (4%-7%) (Casey 1989; Fitton and Heel1990; Stephens 1990; Baldessariniand Frankenburg 1991; Saffermanet al. 1991; Meltzer 1993). Cloza-pine is also associated with alower risk of neuroleptic malignantsyndrome (NMS) (Borison and Di-amond 1990; Fitton and Heel 1990;Safferman et al. 1991; Meltzer1993). Although clozapine has beenclaimed not to cause NMS, thereare case reports of clozapine-induced NMS in patients receivingonly clozapine treatment (Nopouloset al. 1990; Anderson and Powers1991; Miller et al. 1991; Goatesand Escobar 1992). In contrast,there are also case reports ofclozapine being successfully usedin patients with previous historiesof NMS (Stoudemire and Clayton1989; Windhager et al. 1990; Bur-rell et al. 1991; Weller andKomhuber 1992), suggesting thatclozapine may be a viable alterna-tive for patients who developNMS on traditional neuroleptics.
It is unclear if clozapine cancause TD (Kane et al. 1993). Sev-eral authors claim that there areno confirmed cases of clozapine-related TD (Casey 1989; Fitton andHeel 1990; Stephens 1990; Saffer-man et al. 1991; Meltzer 1993), butthere are several case reports ofclozapine exacerbation of TD andclozapine-induced TD (de Leon et
al. 1991; Jann 1991; Kane et al.1993). If clozapine causes TD, itappears that the incidence of TDwith clozapine treatment is mark-edly less than that with traditionalneuroleptics.
There have been several case re-ports and studies examining thepotential therapeutic effect ofclozapine for TD, with some stud-ies documenting the therapeuticvalue of clozapine for diminishingTD (Simpson et al. 1978; Meltzerand Luchins 1984; Small et al.1987; Van Putten et al. 1990;Lieberman et al. 1991; Bajulaiyeand Addonizio 1992; Littrell andMagill 1993; Tamminga et al.1994); however, others have notfound evidence supporting thiseffect (Gerlach et al. 1975; Carrollet al. 1977; Caine et al. 1979;Wirshing et al. 1990).
Discussion
The quality of the studies evaluat-ing clozapine's clinical efficacy forpositive and negative symptoms inacutely psychotic and in treatment-resistant schizophrenia patients,and as a maintenance treatmentfor positive and negative symp-toms, varies widely within eacharea. Multiple double-blind studieshave been conducted examiningthe efficacy of clozapine for thetreatment of acutely ill schizophre-nia patients; however, most ofthese studies are characterized bysmall sample sizes or the use oflow dosages of either clozapine orthe comparison drug. Only threedouble-blind studies have ex-amined the efficacy of clozapine intreatment-resistant schizophreniapatients. The majority of studiesexamining clozapine's efficacy as amaintenance treatment are retro-spective. These studies are limited
by their dependence on medicalrecords as their major source ofinformation, their lack of objectivesymptom ratings, and their failureto use objective criteria to definetreatment response. The prospec-tive studies are characterized bysmall sample sizes and lack ofnonblind ratings of outcomemeasures.
The general quality issue withrespect to the studies examiningthe effect of clozapine on otheroutcome measures is that none ofthe studies are double-blind. Inaddition, there is a relative paucityof literature in each of the areas,especially that of clozapine's effecton cognitive impairments (not re-viewed in this article).
With regard to clozapine'sefficacy for the active symptoms ofschizophrenia, it can be said withsubstantial confidence that it is (1)as effective as traditional neurolep-tics for the reduction of positivesymptoms in acutely psychotic pa-tients, (2) an effective treatment forreducing psychotic symptoms in 30to 60 percent of schizophrenia pa-tients who fail to respond to ade-quate trials of traditional neurolep-tics, (3) an effective maintenancetreatment for positive symptoms,and (4) an effective treatment forhostility.
There is suggestive evidence thatclozapine (1) improves social andoccupational functioning, (2) im-proves patients' quality of life, (3)decreases the rate and length ofhospitalizations, (4) reduces affec-tive symptoms, (5) reduces second-ary negative symptoms, and (6) re-duces TD.
As to clozapine's side effect pro-file, there is substantial evidencethat clozapine is associated withan increased risk for agranulocy-tosis and seizures; that it is associ-
588 SCHIZOPHRENIA BULLETIN
ated with a reduced likelihood ofdeveloping EPS, NMS, and TD;and that it may cause reboundpsychosis if abruptly discontinued.
Needs for Future Research
Several measurement issues needto be addressed in future studies.The first is assessment of negativesymptoms. There has been a gen-eral lack of attention paid to dif-ferentiation of deficit from othernegative symptoms. Future studiesneed to incorporate assessments ofdeficit symptoms (Kirkpatrick et al.1989) in order to be able to evalu-ate the effect of clozapine on thesesymptoms. Second, future studiesshould use instruments that pro-vide detailed evaluations of rolefunctioning, quality of life, andfamily burden. Third, the evalua-tions of clozapine's effect oncognitive functions should beorganized according to specificcognitive functions observed to beabnormal in schizophrenia patients,with detailed evaluations of eachfunction included in the neuropsy-chological assessment battery.
Future investigations shouldfocus on the following areas ofsubstantive interest:
1. Double-blind studies to ex-amine clozapine's efficacy (1) fornegative symptoms, includingwhether such efficacy includesboth deficit and secondary nega-tive symptoms and, if limited tosecondary negative symptoms,what the underlying mechanismsare for this beneficial effect; (2) forcognitive impairments; (3) forquality of life, social and occupa-tional role functioning, and familyburden; and (4) as a maintenancetreatment, including its effect onrelapse and hospitalization rates.
2. Double-blind studies to evalu-ate what constitutes an optimalclozapine treatment trial and whoshould be eligible for clozapinetreatment; that is, what is the op-erational definition of treatmentresistance?
3. Double-blind studies to evalu-ate pharmacological augmentationstrategies for patients who do nothave an adequate response toclozapine.
4. The interaction betweenclozapine treatment and nonphar-macological treatment interventions.
5. The effectiveness of clozapinein nonresearch settings, includingevaluations of factors affecting thepatient's acceptance of or non-compliance with clozapine treat-ment, and factors affecting thephysician's clozapine prescriptionpractices.
References
Alphs, L.D., and Lee, H.S. Com-parison of withdrawal of typicaland atypical antipsychotic drugs: Acase study, journal of Clinical Psy-chiatry, 52:346-348, 1991.
Anderson, E.S., and Powers, P.S.Neuroleptic malignant syndromeassociated with clozapine use. Jour-nal of Clinical Psychiatry, 52:102-104, 1991.
Andreasen, N.C. The Scale for theAssessment of Negative Symptoms(SANS). Iowa City, IA: The Uni-versity of Iowa Press, 1984.
Bajulaiye, R., and Addonizio, G.Clozapine in the treatment of psy-chosis in an 82-year-old womanwith tardive dyskinesia. [Letter]Journal of Clinical Psychopharmacol-ogy, 12:364-365, 1992.
Baker, R.W.; Chengappa, K.N.;Baird, J.W.; Steingard, S.; Christ,M.A.; and Schooler, N.R. Emer-
gence of obsessive compulsivesymptoms during treatment withclozapine. Journal of Clinical Psychi-atry, 53:439-142, 1992.
Baker, R.W., and Conley, R.R. Sei-zures during clozapine therapy.American Journal of Psychiatry,148:1265-1266, 1991.
Baldessarini, R.J., and Frankenburg,F.R. Clozapine: A novel antipsy-chotic agent. New England Journalof Medicine, 324:746-754, 1991.
Banki, CM., and Vojnik, M. Coop-erative simultaneous measurementof cerebrospinal fluid 5-hydroxyin-doleacetic acid and blood serotoninlevels in delirium tremens andclozapine induced delirious reac-tion. Journal of Neurology, Neuro-surgery and Psychiatry, 41:420-424,1978.
Berman, I.; Zalma, A.; DuRand,C.J.; and Green, A.I. Clozapine-induced myoclonic jerks and dropattacks. [Letter] Journal of ClinicalPsychiatry, 53:329-330, 1992.
Borison, R.L., and Diamond, B.I.New advances in psychotherapeu-tic agents: Clozapine. PsychiatricMedicine, 8:13-21, 1990.
Borison, R.L.; Diamond, B.I.; Sinha,D.; Gupta, R.P.; and Ajiboye, P.A.Clozapine withdrawal reboundpsychosis. Psychopharmacology Bul-letin, 24(2):260-263, 1988.
Breier, A.; Buchanan, R.W.; Irish,D.; and Carpenter, W.T., Jr.Clozapine in schizophrenic outpa-tients: II. Outcome and long-termresponse patterns. Hospital andCommunity Psychiatry, 44:1145-1149, 1993.
Breier, A.; Buchanan, R.W.;Kirkpatrick, B.; Davis, O.R.; Irish,D.; Summerfelt, A.; and Carpenter,W.T., Jr. Clozapine in schizo-phrenic outpatients: Effects onpositive and negative symptoms.
VOL. 21, NO. 4, 1995 589
American journal of Psychiatry,151:20-26, 1994.Burrell, M.F.; Fewster, C; Szabadi,E.; and Cashman, M. Clozapine-treated NMS. [Letter] British jour-nal of Psychiatry, 158:577, 1991.
Caine, E.D.; Polinsky, R.J.; Kart-zinel, R.; and Ebert, M.H. The trialuse of clozapine for abnormal in-voluntary movement disorders.American journal of Psychiatry,136:317-320, 1979.
Carroll, B.J.; Curtis, G.C.; and Kok-men, E. Paradoxical response todopamine agonists in tardive dys-kinesia. American journal of Psychi-atry, 134:785-789, 1977.
Carson, W.H., and Forbes, R.A.Clozapine-induced weight gain.[Letter] American journal of Psychi-atry, 147:1694, 1990.
Casey, D.E. Clozapine: Neuroleptic-induced EPS and tardive dys-kinesia. Psychopharmacology,99(Suppl.):47-53, 1989.
Chiles, J.A.; Cohen, S.; andMacNaughton, A. Dropping ob-jects: Possible mild cataplexy asso-ciated with clozapine. Journal ofNervous and Mental Disease,175:663-664, 1990.
Chiu, E.; Burrows, G.; and Steven-son, J. Double-blind comparison ofclozapine with chlorpromazine inacute schizophrenic illness. Aus-tralian and New Zealand journal ofPsychiatry, 10:343-347, 1976.
Claghorn, J.; Honigfeld, G.;Abuzzahab, F.S.; Wang, R.; Stein-book, R.; Tuason, V.; and Klerman,G. The risks and benefits ofclozapine versus chlorpromazine.journal of Clinical Psychopharmacol-ogy, 7:377-384, 1987.
Cohen, S.; Chiles, J.; and Mac-Naughton, A. Weight gain associ-ated with clozapine. American Jour-nal of Psychiatry, 147:503-504, 1990.
Davies, M.A.; Conley, R.R.; Schulz,S.C.; and Bell-Delaney, J. One-yearfollow-up of 24 patients in a clini-cal trial of clozapine. Hospital andCommunity Psychiatry, 42:628-629,1991.de Leon, J.; Moral, L.; andCamunas, C. Clozapine and jawdyskinesia: A case report, journalof Clinical Psychiatry, 52:494-^95,1991.
Devinsky, O.; Honigfeld, G.; andPatin, J. Clozapine-related seizures.Neurology, 41:369-371, 1991.
Ekblom, B.; Eriksson, K.; andLindstrom, L.H. Supersensitivitypsychosis in schizophrenic patientsafter sudden clozapine withdrawal.Psychopharmacology, 83:293-294,1984.
Ekblom, B., and Haggstrom, J.E.Clozapine (Leponex) comparedwith chlorpromazine: A double-blind evaluation of pharmacologicaland clinical properties. CurrentTherapy Research, 16:945-957, 1974.
Eklund, K. Supersensitivity andclozapine withdrawal. [Letter] Psy-chopharmacology, 91:135, 1987.Fischer-Cornelssen, K.A., and Fer-ner, U.J. An example of Europeanmulti-center trials: Multi-spectralanalysis of clozapine. Psychophar-macology Bulletin, 12(2):34-39, 1976.
Fitton, A., and Heel, R.C.Clozapine: A review of its phar-macological properties andtherapeutic use in schizophrenia.Drugs, 40:722-747, 1990.
Gelenberg, A.J., and Doller, J.C.Clozapine versus chlorpromazinefor the treatment of schizophrenia:Preliminary results from a double-blind study, journal of Clinical Psy-chiatry, 40:238-240, 1979.
Gerlach, J.; Koppelhus, P.; Helweg,E.; and Monrad, A. Clozapine andhaloperidol in a single-blind cross-
over trial: Therapeutic and bio-chemical aspects in the treatmentof schizophrenia. Acta PsychiatricaScandinavian, 50:410-424, 1974.
Gerlach, J.; Thorsen, K.; and Fog,R. Extrapyramidal reactions andamine metabolites in cerebrospinalfluid during haloperidol andclozapine treatment of schizo-phrenic patients. Psychopharmacol-ogy, 40:341-350, 1975.
Goates, M.G., and Escobar, J.I. Anapparent neuroleptic malignantsyndrome without extrapyramidalsymptoms upon initiation of cloza-pine therapy: Report of a case andresults of a clozapine rechallenge.[Letter] Journal of Clinical Psycho-pharmacology, 12:139-140, 1992.
Gouzoulis, E.; Grunze, H.; and vonBardeleben, U. Myoclonic epilepticseizures during clozapine treat-ment: A report of three cases.European Archives of Psychiatry andClinical Neuroscience, 240:370-372,1991.
Grohmann, R.; Ruther, E.; Sassim,N.; and Schmidt, L.G. Adverseeffects of clozapine. Psychophar-macology, 99(Suppl.):101-104, 1989.
Guirguis, E.; Voineskos, G.; Gray,J.; and Schlieman, E. Clozapine(Leponex) vs. chlorpromazine(Largactil) in acute schizophrenia(a double-blind controlled study).Current Therapy Research, 21:707-719, 1977.
Haller, E., and Binder, R.L.Clozapine and seizures. Americanjournal of Psychiatry, 147:1069-1071,1990.
Jann, M.W. Clozapine. Phar-macotherapy, 11:179-195, 1991.
Juul-Poulsen, U.; Noring, U.; Fog,R.; and Gerlach, J. Tolerabiliry andtherapeutic effect of clozapine: Aretrospective investigation of 216patients, treated with clozapine for
590 SCHIZOPHRENIA BULLETIN
up to 12 years. Ada PsychiatricaScandinavica, 71:176-185, 1985.Kane, J.M.; Honigfeld, G.; Singer,].; Meltzer, H.Y.; and the ClozarilCollaborative Study Group. Cloza-pine for the treatment-resistantschizophrenic: A double-blind com-parison with chlorpromazine. Ar-chives of General Psychiatry, 45:789-796, 1988.
Kane, J.M.; Woerner, M.G.; Pollack,S.; Safferman, M.D.; and Lieber-man, J.A. Does clozapine causetardive dyskinesia? Journal of Clini-cal Psychiatry, 54:327-330, 1993.
Kirkegaard, A., and Jensen, A. Aninvestigation of some side effectsin 47 psychotic patients duringtreatment with clozapine and dis-continuing of the treatment.Arztneimittel-Forschung/Drug Re-search, 29:851-858, 1979.
Kirkpatrick, B.; Buchanan, R.W.;McKenney, P.D.; Alphs, L.D.; andCarpenter, W.T., Jr. The schedulefor the deficit syndrome: An in-strument for research in schizo-phrenia. Psychiatry Research,30:119-124, 1989.
Krupp, P., and Barnes, P.Clozapine-associated agranulocy-tosis: Risk and aetiology. BritishJournal of Psychiatry, 17:38-40,1992.
Kuha, S., and Miettinen, E. Long-term effect of clozapine in schizo-phrenia: A retrospective study of108 chronic schizophrenics treatedwith clozapine for up to 7 years.Nordisk Psykiatrisk Tidsskrift,40:225-230, 1986.
Lamberti, J.S. Weight gain amongschizophrenic patients treated withclozapine. American Journal of Psy-chiatry, 149:689-690, 1992.
Leadbetter, R.A.; Shutty, M.S.;Pavalonis, D.; and Vieweg, V.Clozapine-induced weight gain:
Prevalence and clinical relevance.American Journal of Psychiatry,149:68-72, 1992.
Leadbetter, R.A., and Vieweg, V.Clozapine-induced weight gain.[Letter] American journal of Psychi-atry, 147:1693-1694, 1990.
Lemus, C.Z.; Lieberman, J.A.; andJohns, C.A. Myoclonus duringtreatment with clozapine andlithium: The role of serotonin. Hill-side Journal of Clinical Psychiatry,11:127-130, 1989.
Leon, C.A. Therapeutic effects ofclozapine: A four-year follow-up ofa controlled clinical trial. Ada Psy-chiatrica Scandinavica, 60:471-480,1979.
Leppig, M.; Bosch, B.; Naber, D.;and Hippius, H. Clozapine in thetreatment of 121 outpatients. Psy-chopharmacology, 99(Suppl.):77-79,1989.
Lieberman, J.A.; Safferman, A.Z.;Pollack, S.; Szymanski, S.; Johns,C.A.; Howard, A.; Kronig, M.;Bookstein, P.; and Kane, J.M. Clini-cal effects of clozapine in chronicschizophrenia: Response to treat-ment and predictors of outcome.American Journal of Psychiatry,151:1744-1752, 1994.
Lieberman, J.A.; Saltz, B.L.; Johns,C.A.; Pollack, S.; Borenstein, M.;and Kane, J.M. The effects ofclozapine on tardive dyskinesia.British Journal of Psychiatry,158:503-510, 1991.
Lindstrom, L.H. The effect of long-term treatment with clozapine inschizophrenia: A retrospectivestudy in 96 patients treated withclozapine for up to 13 years. ActaPsychiatrica Scandinavica, 77:524—529, 1988.
Littrell, K., and Magill, A.M. Theeffect of clozapine on preexisting
tardive dyskinesia. Journal of Psy-chosocial Nursing, 31:14-18, 1993.
Liukkonen, ].; Koponen, H.J.; andNousiainen, U. Clinical picture andlong-term course of epileptic sei-zures that occur during clozapinetreatment. Psychiatry Research,44:107-112, 1992.
Mattes, J.A. Clozapine for refrac-tory schizophrenia: An open studyof 14 patients treated up to twoyears. Journal of Clinical Psychiatry,50:389-391, 1989.
Meltzer, H.Y. Dimensions of out-come with clozapine. British Jour-nal of Psychiatry, 17:46-53, 1992.
Meltzer, H.Y. New drugs for thetreatment of schizophrenia. Psychi-atric Clinics of North America,16:365-385, 1993.
Meltzer, H.Y.; Burnett, S.; Bastani,B.; and Ramirez, L.F. Effects of sixmonths of clozapine treatment onthe quality of life of chronic schiz-ophrenic patients. Hospital andCotnmunity Psychiatry, 41:892-897,1990.
Meltzer, H.Y., and Luchins, D.J.Effect of clozapine in severe tar-dive dyskinesia: A case report.Journal of Clinical Psychopharmacol-ogy, 4:286-287, 1984.
Meltzer, H.Y., and Okayli, G. Re-duction of suicidality duringclozapine treatment of neuroleptic-resistant schizophrenia: Impact onrisk-benefit assessment. AmericanJournal of Psychiatry, 152:183-190,1995.
Miller, D.D.; Perry, P.J.; Cadoret,R.J.; and Andreasen, N.C. Cloza-pine's effect on negative symptomsin treatment refractory schizophre-nia. Comprehensive Psychiatry, 35:8-15, 1994.
Miller, D.D.; Sharafuddin, M.J.;and Kathol, R.G. A case of
VOL. 21, NO. 4, 1995 591
clozapine-induced neuroleptic ma-lignant syndrome, journal of Clini-cal Psychiatry, 52:99-101, 1991.
Nopoulos, P.; Flaum, M.; and Mil-ler, D.D. Atypical neuroleptic ma-lignant syndrome (NMS) with anatypical neuroleptic: Clozapine-induced NMS without rigidity. An-nals of Clinical Psychiatry, 2:251-253, 1990.
Overall, J.E., and Gorham, D.R.The Brief Psychiatric Rating Scale.Psychological Reports, 10:799-812,1962.
Parsa, M.A.; al-Lanham, Y.H.;Ramirez, L.F.; and Meltzer, H.Y.Prolonged psychotic relapse afterabrupt clozapine withdrawal. [Let-ter] Journal of Clinical Psychophar-macology, 13:154-155, 1993.
Patil, V.J. Development of transientobsessive-compulsive symptomsduring treatment with clozapine.[Letter] American journal of Psychi-atry, 149:272, 1992.
Perenyi, A.; Kuncz, E.; and Bagdy,G. Early relapse after suddenwithdrawal or dose reduction ofclozapine. [Letter] Psychopharmacol-ogy, 86:244, 1985.
Pickar, D.; Owen, R.R.; Litman,R.E.; Konicki, E.; Gutierrez, R.; andRapaport, M.H. Clinical and bio-logic response to clozapine in pa-tients with schizophrenia: Cross-over comparison with fluphen-azine. Archives of GeneralPsychiatry, 49:345-353, 1992.
Safferman, A.; Lieberman, J.A.;Kane, J.M.; Szymanski, S.; andKinon, B. Update on the clinicalefficacy and side effects ofclozapine. Schizophrenia Bulletin,17(2):247-261, 1991.
Schuster, P.; Gabriel, E.; Kufferle,B.; Strobl, G.; and Karobuth, M.Reversal by physostigmine of
clozapine-induced delirium. ClinicalToxicology, 10:437-441, 1977.
Shopsin, B.; Klein, H.; Aaronsom,M.; and Collora, M. Clozapine,chlorpromazine, and placebo innewly hospitalized, acutely schizo-phrenic patients: A controlled,double-blind comparison. Archivesof General Psychiatry, 36:657-664,1979.
Simpson, G.M., and Cooper, T.A.Clozapine plasma levels and con-vulsions. American Journal of Psy-chiatry, 135:99-100, 1978.
Simpson, G.M.; Lee, J.H.; andShrivastava, R.K. Clozapine in tar-dive dyskinesia. Psychopharmacol-ogy, 56:75-80, 1978.
Singer, K., and Law, S.K. Adouble-blind comparison ofclozapine (Leponex) and chlorpro-mazine in schizophrenia of acutesymptomatology. Journal of InternalMedicine, 2:433-̂ 135, 1974.Small, J.G.; Milstein, V.; Marhenke,J.D.; Hall, D.D.; and Kellams, J.J.Treatment outcome with clozapinein tardive dyskinesia, neurolepticsensitivity, and treatment-resistantpsychosis. Journal of Clinical Psy-chiatry, 48:263-267, 1987.
Stephens, P. A review of cloza-pine: An antipsychotic fortreatment-resistant schizophrenia.Comprehensive Psychiatry, 31:315-326, 1990.
Stoudemire, A., and Clayton, L.Successful use of clozapine in apatient with a history of neurolep-tic malignant syndrome. Journal ofNeuropsychiatry, 1:303-305, 1989.
Szarek, B.L., and Goethe, J.W. Re-sponse to Chiles and colleagues.[Letter] Journal of Nervous andMental Disease, 180:401, 1992.
Tamminga, C.A.; Thaker, G.K.;Moran, M.; Kakigi, T.; and Gao,
X.-M. Clozapine in tardive dys-kinesia: Observations from humanand animal model studies. Journalof Clinical Psychiatry, 55:102-106,1994.
Tandon, R.; Goldman, R.; De-Quardo, J.R.; Goldman, M.; Perez,M.; and Jibson, M. Positive andnegative symptoms co-vary duringclozapine treatment in schizophre-nia. Journal of Psychiatric Research,27:341-347, 1993.
Van Putten, T.; Wirshing, W.C.;and Marder, S.R. Tardive Meigesyndrome responsive to clozapine.[Letter] Journal of Clinical Psycho-pharmacology, 10:381-382, 1990.Waldman, M.D., and Safferman,A.Z. Pregnancy and clozapine.[Letter] American Journal of Psychi-atry, 150:168-169, 1993.
Weller, M., and Kornhuber, J.Clozapine rechallenge after anepisode of "Neuroleptic MalignantSyndrome." British Journal of Psy-chiatry, 161:855-856, 1992.
Windhager, E.; Leblhuber, F.; andPuhringer, W. Neuroleptic treat-ment after episode of neurolepticmalignant syndrome. [Letter] AdaPsychiatrica Scandinavica, 82:268,1990.
Wirshing, W.C; Phelan, C.K.; VanPutten, T.; Marder, S.R.; andEngel, J. Effects of clozapine ontreatment-resistant akathisia andconcomitant tardive dyskinesia.[Letter] Journal of Clinical Psycho-pharmacology, 10:371-373, 1990.
The Author
Robert W. Buchanan, M.D., is As-sociate Professor of Psychiatry,University of Maryland School ofMedicine, and Chief of the Outpa-tient Program of the MarylandPsychiatric Research Center, Bal-timore, MD.
top related